Navigation Links
t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
Date:5/25/2010

FRANKFURT, May 25, 2010 /PRNewswire/ -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency (EMA).

t2c001 is the first product ever to obtain a certificate under the EMA regulations for Advanced Therapy Medicinal Products (ATMPs). It is a somatic cell therapy product derived from autologous bone marrow, that is currently developed for the treatment of cardiovascular diseases. ATMPs are advanced biotechnology products based on cell therapy, gene therapy, or tissue engineering.

"We are absolutely excited that our lead product has been confirmed to meet the rigorous quality requirements set by the EMA, the regulatory body that will decide on a future European market approval for our product", commented Dr Petra Rueck, CEO of t2cure. "Together with upcoming 5-year efficacy and safety data from our Phase II trial, the EMA Certification shows that we are on the right track to bring this groundbreaking therapy closer to the market, and to patients."

Rueck continued: "This achievement also proves that the regulations set out by the EMA for advanced therapy products and the expertise brought together by the EMA's Committee for Advanced Therapies effectively assist small and medium-sized companies in developing advanced therapy products. These products offer novel treatment opportunities for patients who suffer from diseases, including orphan diseases, for which there are limited or no treatment options."

ATMPs and European Regulation on ATMPs

Advanced therapy medicinal products (ATMPs) base
'/>"/>

SOURCE t2cure GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
2. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Genmab Announces 2007 First Half Year Results
7. Pharsight Achieves First License Sale for Public-Source Database
8. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. China Medical Technologies Reports First Quarter Financial Results
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) ... fostering and monetization of intellectual property, today announced that ... period ending June 30, 2014 on Monday, August 18, ... at 10 a.m. ET on Monday, August 18, 2014 ... led by the company,s CEO, Anthony Hayes . ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a ... the long term. They are the first functional focus ... energy as an alternative to the temporary fix associated ... Indiegogo on July 29, 2014, with hopes to raise ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... , 23 de julio de 2014 /PRNewswire/ ... o la Compañía) ha anunciado hoy una asociación ... (ABIA o el Instituto), para el ... un dispositivo de terapia de señal bioeléctrica (el ... El Instituto, que tiene una importante experiencia ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6
... ... trainer Dr. Rebecca Fitzgerald, known among her medical colleagues as the "Sculptra guru" here in ... physicians at this year,s 4 day SDEF Cosmetic Dermatology Seminar held in Santa Monica, Ca. ... Los Angeles, Ca ...
... , SANTA ANA, Calif. , ... partnership with Prodimed, a company specializing in women,s health, located ... be distributing Prodimed,s extensive line of embryo transfer catheters, oocyte ... , , Prodimed has a ...
... PALO ALTO, Calif., July 21, Varian, Inc. (NasdaqGS: VARI) plans to ... 2009 after 1:00 p.m. Pacific Time (PT) on Wednesday, July 29, 2009. ... review those quarterly results is scheduled to follow at 2:00 p.m. PT ... webcast can be accessed from Varian, Inc.,s Web site at ...
Cached Biology Technology:Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3
(Date:7/23/2014)... drought that has the entire country in its grip is ... also be responsible for the proliferation of a heat-loving amoeba ... and hot springs, which the drought has made warmer than ... of an infection caused by this parasite after swimming in ... nose of an individual and travels to the brain. Nose ...
(Date:7/23/2014)... The Worldwide Innovative Networking in personalized cancer medicine, (the ... Center at Thomas Jefferson University will be ... member of this prestigious group in the Tri-State Area. ... of innovative personalized medicine to the patient by forging ... , "Our participation in the WIN consortium means Jefferson ...
(Date:7/23/2014)... will play an increasingly important role in carbon and ... zones expand, according to research published this week in ... . , University of British Columbia researchers plumbed the ... to chart how microbial community metabolism changes as oxygen ... detailed picture of how SUP05 a bacterial group ...
Breaking Biology News(10 mins):Diseases of another kind 2New partnership brings more personalized cancer treatment to Philadelphia 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... This release is available in French . ... of Medicine and the CHUQ Research Center have proven that ... Duchenne muscular dystrophy. The team, led by Professor Jacques P. ... published today in the online version of the scientific journal ...
... Program will feature new study results from the conference ... their presentation at ELCC): Making EGFR ... radiation in patients with locally advanced lung cancer: first ... lung cancer in organ transplant recipients, Hyperfractionated radiotherapy for ...
... PITTSBURGH, April 15 Certain genetic variations may be ... periodontitis, according to two recently published papers by researchers ... and their collaborators. Alexandre R. Vieira, D.D. S., ... professor of oral biology, and his colleagues at the ...
Cached Biology News:Researchers prove the gene responsible for Duchenne muscular dystrophy can be repaired 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3Pitt Dental School researchers find susceptibility for caries, gum disease in genes 2
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: